|
Invention refers to pharmaceutical industry and represents using sulphated hyaluronic acid for preparing a therapeutic agent for local administration for treating inflammatory/irritating skin diseases specified in dermatitis, atopic dermatitis, photocontact dermatitis, rash, vitiligo, eczema, psoriasis, all skin irritations related to activation of anti-inflammatory cytokines, such as IL-1, IL-2, IL-7, IL-8, IL-9 and TNF, wherein hyaluronic acid has a molecular weight falling within the ranges of 10000 D to 50000 D, 150000 D to 250000 D and 500000 D to 750000 D, and a sulphatation degree equal to 1. |
|
Invention refers to manufacturing pharmaceutical drugs. A drug represents a solution of N,N'-diaminodiphenylsulphone in a mixture of solvents: ethanol and water and at least one of the solvents specified in a group including propylene glycol, benzyl alcohol and glycofurol. Preferentially, the solution contains ethanol 25%, propylene glycol 58%, benzyl alcohol 1%, glycofurol 5% and water 11%. |
|
Antitumour agent, kit and method of treating cancer Group of inventions refers to medicine and concerns an antitumour preparation containing a combination of (1) a combined therapeutic agent S-1, (2) at least one ingredient specified in a group consisting of folinic acid and its pharmaceutically acceptable salts, and (3) cis-oxalate(1R,2R-diaminocyclohexane)platinum(II); a kit for treating cancer in a mammal comprising a combination of the pharmaceutical compositions for treating cancer in the mammal; a method of treating cancer involving administration of the above combination into the mammal. |
|
|
Composition for treatment of infections of bacterial etiology in animals Composition comprises, by wt %: doxycycline hyclate - 5.0-15.0, bromhexine hydrochloride - 0.25-0.75, lactulose - 0.5-1.5, 2-pyrrolidone - the rest. |
|
|
Eye drops, which have anti-infectious, anti-inflammatory and anti-allergic action Invention relates to field of medicine, namely to ophthalmology, and can be applied for treatment of different diseases of eyes. Eye drops contain methylene blue, diphenhydramine hydrochloride, naphazoline hydrochloride, hydroxypropylmethylcellulose, boric acid, polyvinylpyrrolidone and distilled water in defined ratio of components. |
|
|
Medicine for treating tuberculosis Invention refers to pharmaceutical industry and medicine, particularly it is used for treating various forms and localisation of tuberculosis. |
|
|
Derivatives of 1-amino-alkylcyclohexane for treatment of diseases, mediated by mast cells Claimed invention relates to field of pharmaceutics and medicine and deals with medication for treatment or prevention of diseases, mediated by mast cells, including neramexane or its pharmaceutically acceptable salt. |
|
Invention relates to field of medicine, namely to pharmaceutical industry and deals with solid pharmaceutical composition, possessing high physical strength. Claimed invention also presents method of manufacturing solid pharmaceutical composition. Claimed pharmaceutical composition contains 7 varicoloured types of granules in form of capsule. Granules contain, wt %: nikotinamide 1-35; pyridoxine 0.1-8; calcium pantitenate 0.1-15, thiamin 0.1-30; tryptophan 1-30; tocoferol 0.5-5; ascorbic acid 0.1-50; 5-hydroxyanthranyl acid 0.01-10; Riboflavin 0.1-10; folic acid 0.1-6; cyanocobalomin 0.001-6; isoleucin 0.5-10; leucin 0.5-15; lysine 0.5-20; phenylalanine 0.1-5; threonine 0.1-5.0; valin 0.1-8.0; methionine 0.1-15; lactose 1-4.0; ergocalcioferol 1-95.0 and auxiliary substances for obtaining granules. |
|
Method of treating patients suffering pustular skin disorders Invention relates to medicine, particularly to dermatology, more specifically to methods of treating pyoinflammatory skin diseases, particularly furunculosis and acne. The method of treating the patients suffering pustular skin disorders, according to the invention, consists in the fact that the affected and surrounding skin areas are prepared with warm weak antiseptic, dried and further processed with an ointment prepared by thorough mixing on a water bath until smooth: zinc-salicylic paste, Lorinden C, gioxizone, streptocide liniment, synthomycin liniment and retinol acetate in the ratio of 3÷1÷1÷1÷0.8÷0.1 with skin treatment produced 2 times a day. The weak antiseptic is sodium bicarbonate or chamomile infusion at temperature 40-45°C. Besides, water bath temperature is to be 40-50°C, and the ointment is to be prepared is a glass or ceramic container. Face acne requires the affected area to be warmed with a vapour bath before finally applying the ointment. To prevent accidental wipe-out of ointment from the ointment treated skin, it is covered with the napkins attached to healthy skin. To enhance the effect of the ointment applications, the affected skin is exposed to UV lamp and/or sunlight for 10-30 minutes. |
|
Pharmaceutical composition for treating burns Invention refers to a pharmaceutical composition for treating burns containing oxidised dextran of molecular weight 35-65 kDa as an active ingredient; as excipients for symptomatic therapy of burns it contains anaesthesine, polyethylene oxide of molecular weight 1.5-6.0 kDa, metronidazole, phosphatidylcholine and a pharmaceutically acceptable carrier in the following proportions, wt %: oxidized dextran - 0.5-5.0; anaesthesine - 0.5-2.5; polyethylene oxide - 0.5-5.0; metronidazole - 0.1-0.2; phosphatidylcholine - 1.0-2.0; pharmaceutically acceptable carrier - the rest. As a pharmaceutically acceptable carrier, the composition may contain purified water or physiologic saline or 10 mM phosphate buffer with pH 7.4. |
|
Invention refers to an agent for treating drug and alcohol dependences which contains an organic colour. The organic colour is specified in a group containing gentian violet, malachite green oxalate, Sudan Black B, Rhodamine 6G or a mixture of said colours and methylene green. The invention also refers to a method of treating drug or alcohol dependence which consists in the introduction of said agent within the dose range of 0.15 mg to 5 g. |
|
|
Amine derivative possessing npy-y5 receptor antagonist activity, and application thereof Present invention refers to pharmaceutics, medicine and organic chemistry and concerns compounds of formulae presented below, as well as a pharmaceutical composition exhibiting NPY Y5 receptor antagonist activity, or an anorectic composition or an anti-obesity composition containing the compound of formulae presented below |
|
Pharmaceutical antioxidant mixture for local intraarticular therapy Invention relates to medicine and pharmaceutical industry and deals with method of local intra-articular therapy of reactive aseptic inflammation of knee joint. Therapeutic mixture includes solution of ascorbic acid 5% for injections, solution of unitiole 5% for injections, solution of novocain 0.5% for injections, taken in equal volume portions with total volume 3 ml. |
|
|
Methods for production and usage of etoxicombretastatines and prodrugs based thereon Invention relates to new etoxicombretastatines with formula (I) possessing anti-cancer activity, to a pharmaceutical composition containing the proposed compounds as well as to methods for production of some of the proposed compounds where R is a hydroxyl group, an amino group, a phosphate group selected from among disodiumphosphate or ammonium phosphate or inner salt of phosphorylcholine, -NH(COCHR'NH)m-H where R' is hydrogen, a natural amino acid side chain or a phenyl group, while m is an integer from 1 to 3. |
|
Preparation containing biologically active substances Invention refers to a biologically active preparation which contains active substances in a liquid phase in an effective amount. Said preparation represents a disperse system with a liquid disperse phase in a microdrop state stabilised by a dry high-disperse inert hydrophobic disconnector which is silicone dioxide with nano-sized particles. The amount of the liquid disperse phase makes 62-91 wt %, while the amount of the disconnector makes 9-38 wt %. |
|
Method of treating trifacial nerve neuralgia Present invention refers to medicine, namely neurology, and can be used for treating patients with trifacial nerve neuralgia. For this purpose, a drug-induced therapy used to stimulate a re-myelination process is added with applications of tissues wetted in a solution consisting of mixed drugs taken in the following proportions, %: 98% dimethyl sulfoxide solution - 20, 2% lidocaine solution - 40, 2% alcoholic solution of benzocaine - 40. Length of daily applications is 30-45 minutes every 3-4 hours 4-5 times a day. The therapeutic course is 7-10 days. |
|
|
Fluoroalkoxy-combretastatin derivatives, use and synthesis methods thereof In formula I Rf is an alkyl group containing 1-2 carbon atoms, in which 1-5 hydrogen atoms are substituted with 1-5 fluorine atoms, and R is an amine group or an amine group substituted with an amino acid residue of general formula NH(COCHR'NH)-H, where R' is hydrogen, a side chain of natural amino acid which is C1-C4alkyl, possibly substituted with a hydroxy group, a hydroxyl group, disodium or an ammonium phosphate group. The invention also relates to versions of the method of producing compounds of formula I, involving the following steps: fluoroalkylation of 4-hydroxy-3-methoxybenzaldehyde or 4-hydroxybenzaldehyde in the presence of an interphase transfer catalyst, to obtain 4-fluoroalkoxy-3-methoxybenzaldehyde (V) or 4-fluoroalkoxybenzaldehyde (VII), respectively, subsequent selective demethylation (V) with lithium diphenylphosphine and a protection of a hydroxy group or nitration (VII) in the 3rd position. The obtained compounds undergo Wittig reacton using a ylide of 3,4,5-trimethoxybenzyltriphenylphosphonium and the desired product is extracted. |
|
Pathogenic bacteria inhibiting biologically active substances Invention relates to novel biologically active compounds of formula , where substitutes R, R1, R2 and R3 are defined in the formula of invention, and can be obtained using a method which involves reaction of corresponding chloroacetamides with a prepared solution of elementary sulphur with morpholine or piperidine, passing the obtained solution of monothiooxamides through a layer of sorbent and then reaction of monothiooxamides with hydrazine-hydrate, reaction of the obtained compound with aldehydes in dimethyl formamide at room temperature and precipitation with methanol which gives good output of the end product. |
|
Novel derivatives of aminobenzophenone In the compound of general formula R1 represents halogen, C1-4alkyl, or C1-4alkoxy; R2 represents hydrogen, halogen; R3 represents hydrogen, or one or several halogens; R4 represents hydrogen, halogen, R8 or Y1R8; Y1 represents -NRa-; Ra and Rb are similar or different, and each represents hydrogen or C1-4alkyl; R8 represents hydrogen, C1-10alkyl; R7 represents hydrogen, hydroxy, trifluoromethyl, amino, C1-6hydroxyalkyl, C1-4alkoxy, C1-4alkylthio, C1-6alkylamino, C1-4alkoxycarbonyl, -S(O)2R, -COOH, -CONH2, or -NRaC(O)R', where R and R' are similar or different, and each represents hydrogen or C1-3alkyl; R5 represents -COOH, Y2R9, Y2R9Y3R10, C1-6alkyl-Y2R9, C1-10alkyl, or unsaturated C3-8carbocycle, said R5 is substituted with one or several, similar or different substituents, represented by R7; R6 represents hydrogen; Y2 represents -O-, -NRa-, -NRaC(O)NRb-, -NRaC(O)-, -C(O)NRa-, -C(O)-, -NRaC(O)O-, or -OC(O)-; R9 represents C1-10alkyldioxolanyl, C1-10alkylthiazolyl, C1-10alkylmorpholinyl, etc. |
|
2-(2,4-dichloranilino)-1,4-bis(4-methylphenyl)-2-buten-1,4-dion, possessing antimicrobial activity Invention relates to field of organic chemistry, to derivatives of 1,4-diketones, namely to novel biologically active substance -2-(2,4-dichloranilino)-1,4-bis(4-methylphenyl)-2-buten-1,4-dione of formula 1 , which possesses antimicrobial activity and can be applied in medicine. |
|
Method of preventing cytosceletal proteins destruction in sceletal muscles within eccentric load Invention belongs to medicine, notably to sports medicine and aeroastromedicine, and can be used in sportsmen training. For this purpose is used administration of compounds, providing increase of nitric oxide (NO) in skeletal muscles. As such a compound L-arginine may be used. |
|
Pharmaceutical composition based on ladasten Invention relates to field of medicine, in particular to pharmaceutics, and concerns pharmaceutical compositions, which contain as active substance therapeutically effective quantity of ladasten, and as target additives - starch, stearic acid and/or its salt or ludipress and stearic acid and/or its salt with definite ratio of said components. Composition is made in form of pills, contains optimal quantity of target additives, which allows to obtain easy swallowed pills. Pills meet all requirements of State Pharmacopoeia XI edition. |
|
|
Invention refers to medicine, particularly to experimental cardiopharmacology and can be used for correction of endothelial dysfunction that is ensured by simulation of endothelial dysfunction in experiment by daily intraperitoneal introduction to Wistar male rats N-nitro-L-apramiH methyl ester in a dose 25 mg/kg within 7 days. Correction of the dysfunction is enabled by intragastric introduction of Lamotrigine in a dose 8.5 mg/kg once a day. |
|
|
Method of overcoming drug resistance of bacteria and fungi Invention relates to medicine, particularly to clinical microbiology and can be used for treating diseases of microbial nature, caused by strains of bacteria and fungi with multiple-resistance to antimicrobial agents. The method is realised as follows. Combined introduction of antimicrobial agents and aniline dyes into the body is done, where the antimicrobial agents are taken in average therapeutic doses and aniline dyes in subinhibitory concentrations from 0.00063 to 0.0025% of the volume of solution of the introduced antimicrobial agent. |
|
Application of naphthalene derivative as oncological disease treatment medicine Invention claims application of naphthalene derivatives: ethylene blue, anthracene, acridine orange, acriflavine, toluidine blue, violamine R, green sulfonic acid, as cancer cell growth inhibitor for treatment of oncology diseases. Application involves administration of medicine up to three times per day by one-time dosage of 0.1 mg to 2 g in the form of solution or inhalation or water solution. Simultaneously medicine is administered rectally or intravenously in the form of 1-5% ointment or suppository. Tumour and metastasis regression is achieved under effect of indicated compounds for osteosarcoma with metastases in lungs, kidney cancer, ovary carcinoma, squamous cell carcinoma, prostate or rectum adenocarcinoma (with metastases to liver), lymphoma, hepatoma, glioblastoma etc. During therapy tumour and metastases disappeared, blood and urine analyses and patient's weight returned to normal. No recurrences have been registered in 4 years. |
|
Method of sexual attraction (libido) disorder treatment in men Phosphodiesterase inhibitor type 5 that is Sildenafil citrate in unit-dose 12.5 mg is introduced. It is combined with antidepressant Maprolitine (Ludiomil) in unit-dose 5.0 mg daily, once a day. Course of treatment is 30 days. |
|
|
Offered is application Aplydine for production of medical product for leukaemia or lymphoma treatment by means of combined therapy using Aplydine and other medical product chosen from group consisting of methotrexate, cytosine arabinoside, mythoxanthrone, vynblastine, methylprennisolone and doxyrubicine, related methods of treatment (versions), pharmaceutical composition and kit. Cancer synergism of listed agents is shown in combination with Aplydine. |
|
Method of complex intensive therapy of children acute stenosing laryngotracheitis Treatment staged larynx stenosis compensation is performed. Medicinal agents are introduced through inhalations by means of nebulyser. For this purpose pulmycort, lasolvane and physiological solution of 0.9% sodium chlorides are used. Children with body weight less than 20 kg take inhalations of pulmycort dosed 250 mcg twice within one hour and then dosed 250 mcg every 12 hours. Lasolvan is inhaled in dose 7.5 mg every 8 hours. Physiological solution 0.9% is inhaled in dose of 5.0 ml every 6 hours of therapy course. Then inhalations are taken every 2 hours during first day. Then Inhalations are taken every 3 hours until laryngotracheitis symptoms stop. Children with body weight more than 20 kg are given wit double dose of pulmycort and lasolvan. |
|
|
Using derivatives of aniline as phosphodiesterase-4 inhibitors Invention relates to novel derivatives of aniline of the general formula (I): and their pharmaceutically acceptable salts and isomeric forms possessing properties of phosphodiesterase-4 inhibitors. Compounds can be used, fore example, for enhancing cognitive ability. In compounds of the general formula (I) R1 means linear or branched (C1-C4)-alkyl that can be unsubstituted or substituted with one or more halogen atoms; R2 means linear or branched (C1-C4)-alkyl that can be unsubstituted or substituted with one or more substitutes of the following order: halogen atom, (C1-C4)-alkoxy or their combinations, (C3-C10)-cycloalkyl, (C4-C16)-cycloalkylalkyl wherein alkyl fragment comprises from 1 to 4 carbon atoms, (C7-C11)-arylalkyl wherein aryl fragment comprises 6 carbon atoms, and alkyl fragment that can be linear or branched and comprises from 1 to 5 carbon atoms and wherein radical arylalkyl can be unsubstituted or substituted in aryl fragment with one or more substitutes of the following order: halogen atom, alkoxy group comprising from 1 to 4 carbon atoms or their combinations, and in alkyl fragment one group -CH2CH2- is optionally replaced for group -CH=CH-, and one group -CH2- is optionally replaced for -O- for -NH-, partially unsaturated carbocyclic group comprising from 5 to 9 carbon atoms that can comprise condensed benzene ring, heterocyclic group that can be saturated, partially saturated or unsaturated and comprises from 5 to 6 carbon atoms in cycle including one atom chosen from oxygen (O), or heterocyclylalkyl group wherein heterocyclic fragment can be saturated, partially saturated or unsaturated and comprises from 5 to 6 carbon atoms in cycle including 1-2 atoms chosen from nitrogen (N) or sulfur (S) atoms, and alkyl fragment that can be linear or branched comprises from 1 to 5 carbon atoms; R3 means partially unsaturated carbocyclylalkyl group wherein carbocyclic fragment comprises from 5 to 6 carbon atoms, and linear or branched alkyl fragment comprises from 1 to 5 carbon atoms, (C7-C11)-arylalkyl wherein aryl fragment comprises 6 carbon atoms, and linear or branched alkyl fragment comprises from 1 to 5 carbon atoms and wherein arylalkyl radical can be linear or substituted in aryl fragment with one or more substitutes of the following group: trifluoromethyl, (C1-C4)-alkyl, (C1-C4)-alkoxy or their combinations, heterocyclylalkyl group wherein heterocyclic fragment can be aromatic, partially or completely saturated and comprises from 5 to 10 atoms in cycle including 1-2 atoms chosen from N, O or S, and linear or branched alkyl fragment comprises from 1 to 5 carbon atoms and wherein heterocyclylalkyl group can be linear or substituted in heterocyclic fragment with one or more substitutes of the following order: halogen atom, (C1-C4)-alkyl, (C1-C4)-alkoxy or their combinations; R4 means (C6-C12)-aryl that can be linear or substituted with one or more substitutes of the following order: halogen atom, (C1-C4)-alkyl, (C2-C4)-alkenyl, hydroxy, (C1-C4)-alkoxy, (C2-C4)-alkoxyalkoxy, nitro, trifluoromethyl, -OCF3, amino group, aminoalkyl, aminoalkoxy, hydroxy-(C1-C4)-alkyl, hydroxamic acid, tetrazol-5-yl, 2-(heterocyclyl)-tetrazol-5-yl, carboxy, alkoxycarbonyl, cyano, acyl, alkylsulfonyl, phenoxy, trialkyloxy, R5-L or their combinations, or heteroaryl comprising from 5 to 10 atoms in cycle including 1-2 atoms chosen from N wherein heteroaryl can be linear or substituted with one or more substitutes of the following order: (C1-C4)-alkyl, (C1-C4)-alkoxy, carboxy, alkoxycarbonyl or their combinations; R5 means hydrogen atom, (C1-C8)-alkyl, (C3-C10)-cycloalkyl, C6-aryl, heterocyclic group that can be saturated, partially saturated or unsaturated and comprises from 5 to 10 atoms in cycle from which at least atom means N or O, and wherein heterocyclic group can be linear or substituted with one or more (C1-C4)-alkyls, or group heterocyclylalkyl, and others. Also, invention relates to intermediates compounds and to a method for enhancing the cognitive ability. |
|
Combinations containing alpha-2-delta ligands and serotonin/noradrenaline reuptake inhibitors Invention describes a combination used in therapeutic, prophylactic or palliative treatment of pain. Proposed combination consists of the following components: (a) alpha-2-delta ligand chosen from habapentine, prehabaline, [(1R,5R,6S)-6-(aminomethyl)bicyclo[3.2.0]hept-6-yl]acetic acid, 3-(1-aminomethylcyclohezylmethyl)-4H-[1.2.4]oxadiazol-5-one, C-[1-(1H-tetrazol-5-ylmethyl)cycloheptyl]methylamine, (3S,4S)-(1-aminomethyl-3,4-dimethylcyclopentyl)acetic acid, (1α,3α,5α)-(3-aminomethylbicyclo[3.2.0]hept-3-yl)acetic acid, (3S,5R)-3-aminomethyl-5-methyloctanoic acid, (3S,5R)-3-methylheptanoic acid, (3S,5R)-3-amino-5-methylnonanoic acid and (3S,5R)-3-amino-5-methyloctanoic acid, or pharmaceutically acceptable salts of any of them, and (b) S,S-reboxetine or its pharmaceutically acceptable salt wherein alpha-2-delta ligand and S,S-reboxetine are taken in the range of ratio from 1:10 to 10:1 of mass parts. Proposed combination provides decreasing the dose of each substance that results to declining adverse effects and enhancing clinical utility of compounds. Also, invention describes using this combination and a set comprising this combination. |
|
Combination of cyclooxygenase 2 inhibitor and histone deacetylase inhibitor Invention relates to a method for preparing a combination comprising (a) cyclooxygenase 2 inhibitor (COX 2 inhibitor) chosen from a compound of the general formula (I): , and (b) histone deacetylase inhibitor chosen from N-hydroxy-3-[4-[[[2-(2-methyl-1H-indole-3-yl)ethyl]amino]methyl]phenyl-2E-2-propenamide for simultaneous, combined, separate of successive using. Proposed composition elicits the expressed synergistic effect in treatment of pretumor damages of colon or colon cancer or other malignant tumors in mammal, especially, in humans. |
|
The present innovation deals with compounds of formula IV , or their acidoadditive salts, methods of their obtaining and application while applying medicinal preparation for treating osseous diseases associated with increased calcium loss or resorption or when the stimulation of osteogenesis and fixation of bone calcium are required. |
|
Invention relates to novel compounds of the formula (I): their pharmaceutically acceptable salts or solvates, or stereoisomers possessing properties of agonists of β2-adrenoreceptors, to pharmaceutical composition based on thereof, using the claimed compounds in manufacturing a medicinal agent, and to a method for modulation of β2-adrenergic receptors. In the formula (I) each among R1-R5 is chosen independently from group comprising hydrogen atom, (C1-C4)-alkyl and Ra wherein alkyl is substituted optionally with substituted chosen from Rb; or R4 and R5 are combined to form group of the formula: -NRdC(=O)C(Rd)=C(Rd)-; R6, R7 and R8 represent hydrogen atom; R9 represents (C1-C4)-alkyl; R10 represents hydrogen atom or (C1-C4)-alkyl; each among R11, R12 and R13 is chosen independently from group including hydrogen atom, (C1-C4)-alkyl, vinyl, cyclohexyl, phenyl, halogen atom, -CO2Rd, -ORd, -S(O)mRd, -N(NRdRe)Rd or -S(O)2NRdRe, 5-6-membered monocyclic heteroaryl comprising 1 or 2 heteroatoms chosen from nitrogen (N), sulfur (S) atoms, 9-membered bicyclic heteroaryl comprising N as a heteroatom and 5-membered heterocycle comprising N as a heteroatom; or R11 and R12 in common with atoms to which they are bound form 6- or 7-membered heterocyclic ring comprising oxygen (O) atom as a heteroatom and wherein for R11-R13 each phenyl or heteroaryl is substituted optionally with 1 or 2 substitutes chosen independently from Rc, and each heterocyclyl is substituted optionally with 1 or 2 substitutes chosen from Rb and Rc; alkyl is substituted optionally with substitute chosen from Rb, and vinyl is substituted optionally with substitute chosen from Rm; w = 0, 1, 2, 3 or 4. Values Ra, Rb, Rc, Rd, Rm and m are given in the invention claim. |
|
Method for selection in individual treatment of patients with bronchial asthma Method involves sampling sputum after inhalation with sodium chloride hypertonic solution followed by cytological analysis of sputum. Inhalations with steroid are carried out in case of detection of candidas, eosinophilia in sputum, and degranulation and lysis of cells also. Pulse-therapy with steroids is carried out in case of detection of eosinophilia in sputum and degranulation of cells. Inhalations and pulse-therapy with steroids are carried out in case of detection of eosinophilia in sputum and degranulation and lysis of cells. In each case treatment is carried out in combination with broncholytics and secretolytics. Method provides enhancing the effectiveness of treatment of bronchial asthma based on individual selection of the selective schedule of therapy and depending on state of microflora and cytology indices of sputum. Invention cab used in complex treatment of patients with bronchial asthma. |
|
|
Mucolytic pharmaceutical composition Claimed composition contains therapeutically effective amount of bromohexin as active ingredient and sugar, starch and stearinic acid salt as target additives. Pharmaceutical composition is provided in form of tablets. |
|
Invention proposes pharmaceutical compositions consisting of multiple particles with sustained-release of serotonin reuptake selective inhibitor (SRSI) with membrane cover comprising ammonium-methacrylate copolymer, or compositions comprising SRSI particles mixture, or compositions comprising SRSI particles mixture in form of sustained-release of SRSI, Also, invention relates to method for treatment of depression involving administration of these compositions. In particular, SRSI represents fluoxetine, fluvoxamine, sertraline or their salt. Proposed compositions provide a less index of fluctuations that reflects lower values of maximal concentrations of substance in plasma blood after multiple administrations, safety and good tolerance also. |
|
Invention represents a healing agent used for close and treatment of suppurative-necrotic and infected wounds, burns, trophic ulcers. Proposed composition comprises the following components taken in the required ratio: water-soluble chitosan of natural origin, polyalkyleneguanides phosphopag and biopag, proteolytic enzymes pepsin and collagenases, ascorbic acid and anesthetic agent. Agent shows the combined wound-healing, bacteriostatic and immunostimulating properties, it stimulates regenerative-reparative processes and accelerates growth of wound healthy cells. Also, agent decreases number of little use and/or expensive components used in preparing wound-healing agents. |
|
|
Method for preventing endometritis after caesarean operation Uterine cavity should be drained in the course of operation, moreover, irrigator's distal end should be withdrawn through operation wound at anterior abdominal wall, and 2 h after the end of operation uterine cavity should be washed through irrigator with 400 ml of cooled 0.06%-sodium hypochlorite solution at perfusion rate being 200 ml/h, 6 times every 12 h up to 3-4 d; after each perfusion one should introduce 1 g kanamycin directly into uterine cavity, moreover, in case of availability of bacterioid and/or anaerobic flora in uterine cavity according to the results obtained due to pre-operational antibioticogram one should add 100 ml 3%-hydrogen peroxide solution into perfusion solution. The present innovation enables to efficiently sanitize uterine cavity due to intrauterine injection of antibiotics by taking into account antibioticogram performed at all stages of operative treatment. |
|
|
Invention relates to agents stimulating the central nervous system, i. e. psychomotor stimulators. Invention proposes combination of sydnocarbum with ladastenum taken in the ratio = 1:(0.4-2) as an agent. Invention provides enhancing physical working ability, prevents the development of acute physical fatigue and exceeds effect of sydnocarbum and ladastenum by 2.7 and 1.6 times, respectively. |
|
Aminobenzophenones as inhibitors il-β and tnf-α Invention relates to a medicinal agent used for treatment of acne and pharmaceutical composition able to inhibit the secretion of IL-1β, TNF-α or PMN-superoxide and comprising compound of the formula (I): Invention provides the enhanced effectiveness of agent. |
|
Invention proposes new compounds of the general formula (I): |
|
Method for treating relapses of uterine cervix cancer The present innovation deals with treating patients with uterine cervix cancer with relapses in parametral fiber and in case of no possibility for radical operative interference and effect of previous radiation therapy. During the 1st d of therapy one should intravenously inject 30 mg platidiam incubated for 1 h at 37 C with 150 ml autoblood, during the next 3 d comes external irradiation per 2.6 G-r. During the 5th d of therapy one should introduce the following composition into presacral space: 60 ml 0.5%-novocaine solution, 1 ml hydrocortisone suspension, 2 ml 50%-analgin solution, 1 ml 0.01%-vitamin B12 solution, 1.6 g gentamycine, 800 mg cyclophosphan, 10 mg metothrexate. These curative impacts should be repeated at mentioned sequence four times. The method enables to decrease radiation loading and toxic manifestations of anti-tumor therapy at achieving increased percent of tumor regression. |
Another patent 2550905.